gms | German Medical Science

27. Deutscher Krebskongress

Deutsche Krebsgesellschaft e. V.

22. - 26.03.2006, Berlin

Potentials and limitations of genetically modified mice

Meeting Abstract

Suche in Medline nach

  • corresponding author presenting/speaker Robert Feil - Interfakultäres Institut für Biochemie, Universität Tübingen, Deutschland

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocIS030

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dkk2006/06dkk030.shtml

Veröffentlicht: 20. März 2006

© 2006 Feil.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

The ability to modify the mouse genome at predetermined sites by homologous recombination in embryonic stem cells has greatly advanced our understanding of mammalian gene function. This method introduces a permanent genetic alteration into the mouse germ line and is being used, for instance, to generate “global” gene knockouts that are present in every cell of the animal. In addition, recent advances allow conditional, i.e. spatio-temporally controlled, genome manipulations in somatic cells of the mouse. Using the Cre/lox site-specific recombination system it is now possible to activate or inactivate a selected gene, at a chosen time, in a specific cell type of living mice, offering unprecedented possibilities for generating animal models for human diseases. We have developed an inducible Cre/lox system that can be switched on by administration of the synthetic drug tamoxifen (the so-called tamoxifen system) and have used this technique to study proliferative disorders such as atherosclerosis. Likewise, a new generation of mouse tumor models became reality with the ability to induce somatic mutations of selected oncogenes or tumor suppressor genes in a temporally defined and tissue-specific manner. The potentials and limitations of these new technological developments will be discussed, with a focus on modelling cancer in mice.